Bringing HIV Prevention DTC: Q&A with Ashley Gildea

Why It Matters

Expanding DTC outreach for long‑acting PrEP could close the awareness gap, boost adherence, and ultimately lower new HIV infections in the United States.

Key Takeaways

• Yeztugo offers six‑month PrEP dosing, reducing clinic visits.
• Campaign uses music, inclusive storytelling to normalize HIV prevention.
• Targets 2.2 million potential US PrEP users, addressing awareness gaps.
• Multi‑channel DTC strategy combines digital, TV, community outreach.
• Success measured by awareness, site traffic, provider discussions.

Pulse Analysis

Direct‑to‑consumer advertising has become a pivotal channel for pharmaceutical firms seeking to engage patients outside the clinic, and Gilead’s Yeztugo launch exemplifies this shift. While traditional PrEP options rely on daily oral dosing or monthly injections, Yeztugo’s six‑month injectable format tackles a core adherence barrier: the need for frequent medical visits. By reducing the visit frequency, the product aligns with broader consumer expectations for convenience, positioning itself as a compelling alternative for both existing PrEP users and those hesitant to start.

The campaign’s creative backbone—leveraging a re‑imagined early‑2000s hit and culturally resonant visuals—signals a move toward purpose‑driven storytelling in pharma marketing. Rather than a clinical pitch, the “One2PrEP” spot frames HIV prevention as a normal, everyday conversation, directly confronting stigma that has historically limited uptake. Multi‑channel distribution across streaming platforms, social media, and community events ensures the message meets diverse audiences where they spend time, reinforcing inclusivity and accessibility.

From an industry perspective, Yeztugo’s rollout offers a template for measuring DTC effectiveness beyond impressions. Gilead’s focus on website traffic, social engagement, and, crucially, the increase in provider‑patient dialogues provides a data‑rich feedback loop that can inform future product launches. If successful, this approach could accelerate the adoption of long‑acting preventive therapies across therapeutic areas, reshaping how pharma balances education, brand building, and health outcomes in a digitally driven marketplace.